Biofrontera (Biofrontera) GF Score : 30/100 (As of Jun. 08, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biofrontera GF Score?

Biofrontera has the GF Score of 30, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Biofrontera might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Biofrontera's GF Score

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera's GF Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's GF Score distribution charts can be found below:

* The bar in red indicates where Biofrontera's GF Score falls into.

Biofrontera (NAS:BFRI) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Biofrontera GF Score Related Terms

Thank you for viewing the detailed overview of Biofrontera's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera (Biofrontera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Presidential Way, Suite 330, Woburn, MA, USA, 01801

Website

https://www.biofrontera-us.com

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Executives

Heikki Lanckriet	director	C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler	officer: Chief Financial Officer	84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber	director	119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii	director	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman	director	5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge	director	21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera	10 percent owner	HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates	officer: Controller	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco	director, officer: Chief Financial Officer/COO	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert	director, officer: Chief Executive Officer	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801